 Kala Pharmaceuticals Inc NASDAQ: KALA shares are trading higher after the company said it would sell its EYSUVIS and INVELTYS treatments for 60 million. Kala Pharmaceuticals is selling its commercial portfolio and related intellectual property assets to Alcon. 